Review article · 2010 · Open access
Second-generation antipsychotics for major depressive disorder and dysthymia
Cochrane Database of Systematic Reviews, 2012(2), CD008121 · Published 29 November 2010 · DOI 10.1002/14651858.cd008121.pub2
In brief
“Second-generation antipsychotics for major depressive disorder and dysthymia” is a 2010 review article by Katja Komossa and 4 co-authors, published in Cochrane Database of Systematic Reviews. OpenAlex counts 204 citations as of 20 November 2026, which puts it in the top 5% of works published in 2010 by citations. It is open access: the full text is free to read at Europe PMC (PubMed Central).
- Citations
- 204
- Most cited in
- 2021 (22)
- Field-weighted impact
- 1.68
- References
- 93
- Authors
- 5
Abstract
BACKGROUND: Major depressive disorder (MDD) is a common condition with a lifetime prevalence of 15% to 18%, which leads to considerable suffering and disability. Some antipsychotics have been reported to induce remission in major depression, when added to an antidepressant. OBJECTIVES: To evaluate the effects of second-generation antipsychotic (SGA) drugs (alone or augmentation) compared with placebo or antidepressants for people with MDD or dysthymia. SEARCH STRATEGY: The Cochrane Depression, Anxiety and Neurosis Group's controlled trial registers (CCDANCTR-Studies and CCDANCTR-References) were searched up to 21 July 2010. The author team ran complementary searches on clinicaltrials.gov and contacted key authors and drug companies. SELECTION CRITERIA: We included all randomised, double-blind trials comparing oral SGA treatment (alone or augmentation) with other forms of pharmaceutical treatment or placebo in people with MDD or dysthymia. DATA COLLECTION AND ANALYSIS: We extracted data independently. For dichotomous data we calculated the odds ratio (OR) and 95% confidence interval (CI) on an intention-to-treat basis, and for continuous data the mean difference (MD), based on a random-effects model. We presented each comparison separately; we did not perform a pooled data analysis. MAIN RESULTS: We included 28 trials with 8487 participants on five SGAs: amisulpride, aripiprazole, olanzapine, quetiapine and risperidone.Three studies (1092 participants) provided data on aripiprazole augmentation in MDD. All efficacy data (response n = 1092, three RCTs, OR 0.48; 95% CI 0.37 to 0.63), (MADRS n = 1077, three RCTs, MD -3.04; 95% CI -4.09 to -2) indicated a benefit for aripiprazole but more side effects (weight gain, EPS) .Seven trials (1754 participants) reported data on olanzapine. Compared to placebo fewer people discontinued treatment due to inefficacy; compared to antidepressants there were no efficacy differences, olanzapine augmentation showed symptom reduction (MADRS n = 808, five RCTs, MD -2.84; 95% CI -5.48 to -0.20), but also more weight or prolactin increase.Quetiapine data are based on seven trials (3414 participants). Compared to placebo, quetiapine monotherapy (response n = 1342, three RCTs, OR 0.52; 95% CI 0.41 to 0.66) and quetiapine augmentation (response n = 937, two RCTs, OR 0.68; 95% CI 0.52 to 0.90) showed symptom reduction, but quetiapine induced more sedation.Four trials (637 participants) presented data on risperidone augmentation, response data were better for risperidone (n = 371, two RCTs, OR 0.57; 95% CI 0.36 to 0.89) but augmentation showed more prolactin increase and weight gain.Five studies (1313 participants) presented data on amisulpride treatment for dysthymia. There were some beneficial effects compared to placebo or antidepressants but tolerability was worse. AUTHORS' CONCLUSIONS: Quetiapine was more effective than placebo treatment.…
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Komossa, K., Depping, A. M., Gaudchau, A., Kissling, W., & Leucht, S. (2010). Second-generation antipsychotics for major depressive disorder and dysthymia. Cochrane Database of Systematic Reviews, 2012(2), CD008121. https://doi.org/10.1002/14651858.cd008121.pub2
MLA 9
Komossa, Katja, et al. “Second-generation antipsychotics for major depressive disorder and dysthymia.” Cochrane Database of Systematic Reviews, vol. 2012, no. 2, 2010, p. CD008121. https://doi.org/10.1002/14651858.cd008121.pub2.
Chicago
Komossa, Katja, Anna M Depping, Andrea Gaudchau, Werner Kissling, and Stefan Leucht. 2010. “Second-generation antipsychotics for major depressive disorder and dysthymia.” Cochrane Database of Systematic Reviews 2012 (2): CD008121. https://doi.org/10.1002/14651858.cd008121.pub2.
Harvard
Komossa, K. et al. (2010) ‘Second-generation antipsychotics for major depressive disorder and dysthymia’, Cochrane Database of Systematic Reviews, 2012(2), p. CD008121. doi:10.1002/14651858.cd008121.pub2.
IEEE
K. Komossa, A. M. Depping, A. Gaudchau, W. Kissling, and S. Leucht, “Second-generation antipsychotics for major depressive disorder and dysthymia,” Cochrane Database of Systematic Reviews, vol. 2012, no. 2, p. CD008121, 2010, doi: 10.1002/14651858.cd008121.pub2.
BibTeX
@article{komossa2010second,
title = {{Second-generation antipsychotics for major depressive disorder and dysthymia}},
author = {Komossa, Katja and Depping, Anna M and Gaudchau, Andrea and Kissling, Werner and Leucht, Stefan},
journal = {Cochrane Database of Systematic Reviews},
year = {2010},
volume = {2012},
number = {2},
pages = {CD008121},
doi = {10.1002/14651858.cd008121.pub2},
url = {https://doi.org/10.1002/14651858.cd008121.pub2}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2017 | 12 | |
| 2018 | 9 | |
| 2019 | 10 | |
| 2020 | 9 | |
| 2021 | 22 | |
| 2022 | 14 | |
| 2023 | 10 | |
| 2024 | 5 | |
| 2025 | 3 | |
| 2026 | 7 |
Its field-weighted citation impact is 1.68: it has been cited 1.68 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- atypical antipsychotics
- major depressive disorder
- dysthymia
- antidepressant augmentation
- aripiprazole
- olanzapine
- amisulpride
- quetiapine
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Komossa, K., Depping, A. M., Gaudchau, A., Kissling, W., & Leucht, S. (2010). Second-generation antipsychotics for major depressive disorder and dysthymia. Cochrane Database of Systematic Reviews, 2012(2), CD008121. https://doi.org/10.1002/14651858.cd008121.pub2
How many times has this paper been cited?
204 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Europe PMC (PubMed Central): sign in and open the full text from this page.
Who wrote this paper?
Katja Komossa, Anna M Depping, Andrea Gaudchau, Werner Kissling, Stefan Leucht.
What is the DOI of this paper?
10.1002/14651858.cd008121.pub2, permanently at https://doi.org/10.1002/14651858.cd008121.pub2. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.